Prof Fran Balkwill
Deputy Lead, Centre for Tumour Microenvironment
Barts Cancer Institute
Queen Mary University of London
Queen Mary University of London
Research
cancer, tumour microenvironment, multi-cellular models, ovarian cancer, extracellular matrix, immunotherapy
Interests
The interest and experience of my laboratory relates to complex multi-cellular models MCMs of the tumour microenvironment, especially in ovarian cancer. Having completed a multi-level deconstruction of ovarian cancer metastases, we have begun to reconstruct 3D multi-cellular models of these metastases using primary adipocytes, fibroblasts, mesothelial cells, monocytes and malignant cells. We are also currently working to vascularise these MCMs. We are using the models to understand cell cell communication in the tumour microenvironment, test new biological therapies and study sensitivity and resistance to T cell killing.Publications
2025
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.Kenny HA, Ip CKM, Kelliher L, Samantaray T, Kordylewicz K, Hoffmann R, Rauch S, Malacrida B et al.
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr), of1-of13.
28-04-2025
2024
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancerElorbany S, Berlato C, Carnevalli LS, Maniati E, Barry ST, Wang J, Manchanda R, Kzhyshkowska J et al.
Nature Communications, Springer Nature vol. 15 (1)
22-11-2024
Protocol for real-time monitoring of CD8+ T and myeloid cell behavior in human high-grade serous ovarian cancer slicesLaforêts F, Donnadieu E, Balkwill F
Star Protocols, Elsevier vol. 5 (2)
01-06-2024
Human 3D ovarian cancer models reveal 1 malignant cell intrinsic and extrinsic factors that 2 influence CAR T cell activityJoy J, Manchanda R, Balkwill F
Cancer Research
31-05-2024
P33 Skinvaders: gamification of the skin barrier to engage school-age children in the biology of the skinde Brito M, Green F, McCarthy R, Rees M, Balkwill F, O’Toole EA
British Journal of Dermatology, Oxford University Press (Oup) vol. 190 (6), e94-e95.
17-05-2024
Correction: Developmental Trajectories of Adolescents’ Math Motivation: The Role of Mindset and Perceptions of Informal STEM Learning Site InclusivityOzturk E, Zhao M, Hoffman AJ, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ et al.
Journal of Youth and Adolescence, Springer Nature vol. 53 (8), 1940-1940.
10-04-2024
The relations between growth mindset, motivational beliefs, and career interest in math intensive fields in informal STEM youth programsOzturk E, Zhao M, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ, Hoffman AJ et al.
Plos One, Public Library of Science (Plos) vol. 19 (4)
09-04-2024
Developmental Trajectories of Adolescents’ Math Motivation: The Role of Mindset and Perceptions of Informal STEM Learning Site InclusivityOzturk E, Zhao M, Hoffman AJ, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ et al.
Journal of Youth and Adolescence, Springer Nature vol. 53 (7), 1542-1563.
28-02-2024
2023
Investigating the impact of London’s ultra low emission zone on children’s health: children’s health in London and Luton (CHILL) protocol for a prospective parallel cohort studyTsocheva I, Scales J, Dove R, Chavda J, Kalsi H, Wood HE, Colligan G, Cross L et al.
Bmc Pediatrics, Springer Nature vol. 23 (1)
04-11-2023
CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cellsSamain R, Maiques O, Monger J, Lam H, Candido J, George S, Ferrari N, KohIhammer L et al.
Science Advances, American Association For The Advancement of Science (Aaas) vol. 9 (42)
18-10-2023
Reciprocal Associations Between Science Efficacy, STEM Identity and Scientist Career Interest Among Adolescent Girls within the Context of Informal Science LearningZhao M, Ozturk E, Law F, Joy A, Deutsch AR, Marlow CS, Mathews CJ, McGuire L et al.
Journal of Youth and Adolescence, Springer Nature vol. 53 (2), 472-484.
11-10-2023
Interferon epsilon and ovarian cancerElorbany S, Malacrida B, Balkwill F
Trends in Cancer, Elsevier vol. 9 (12), 985-986.
29-09-2023
Children's and adolescents’ evaluations of wealth‐related STEM inequalityMcGuire L, Marlow C, Hoffman AJ, Joy A, Law F, Hartstone‐Rose A, Rutland A, Winterbottom M et al.
Social Development, Wiley vol. 33 (1)
22-09-2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports, Springer Science and Business Media Llc vol. 75 (3), 753-753.
17-05-2023
Device-Measured Change in Physical Activity in Primary School Children During the UK COVID-19 Pandemic Lockdown: A Longitudinal StudyScales J, Chavda J, Ikeda E, Tsocheva I, Dove RE, Wood HE, Kalsi H, Colligan G et al.
Journal of Physical Activity and Health, Human Kinetics vol. 20 (7), 639-647.
04-05-2023
Abstract LB195: Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancerElorbany S, Berlato C, Carnevalli L, Maniati E, Wang J, Barry S, Manchanda R, Kzhyshkowska J et al.
14-04-2023
The impact of pericytes on the stability of microvascular networks in response to nanoparticlesDibble M, Di Cio’ S, Luo P, Balkwill F, Gautrot JE
Scientific Reports, Springer Nature vol. 13 (1)
07-04-2023
Abstract 5957: Chemotherapy-induced extracellular matrix remodeling in HGSOCKotantaki P, Laforêts F, Maniati E, Berlato C, Malliouri A, Devlin MJ, Malacrida B, Elorbany S et al.
04-04-2023
Abstract 5913: Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatmentsLaforets F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, Balkwill F
04-04-2023
Abstract 4551: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cellsMalacrida B, Elorbany S, Maniati E, Laforets F, Manchanda R, Balkwill FR
04-04-2023
Abstract 4576: 3D in vitro models uncover malignant cell intrinsic and extrinsic mechanisms of CAR-T cell resistance in high grade serous ovarian cancerJoy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Hopkins S, Garrobo-Calleja I, Gautrot J et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (7_Supplement), 4576-4576.
04-04-2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports, Springer Science and Business Media Llc vol. 75 (3), 570-584.
03-04-2023
Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatmentsLaforêts F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, Balkwill F
Iscience, Elsevier vol. 26 (4)
29-03-2023
Interest, Mindsets and Engagement: Longitudinal Relations in Science Orientations for Adolescents in Informal Science ProgramsJoy A, Mathews CJ, Zhao M, Law F, McGuire L, Hoffman AJ, Balkwill F, Burns KP et al.
Journal of Youth and Adolescence, Springer Nature vol. 52 (5), 1088-1099.
06-02-2023
2022
A factorial randomised trial investigating factors influencing general practitioners’ willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a registered reportLloyd KE, Hall LH, Ziegler L, Foy R, Borthwick GM, MacKenzie M, Taylor DG, Smith SG
British Journal of General Practice, Royal College of General Practitioners vol. 73 (729)
14-12-2022
Promoting Diverse Youth’s Career Development through Informal Science Learning: The Role of Inclusivity and BelongingZhao M, Mathews CJ, Mulvey KL, Hartstone-Rose A, McGuire L, Hoffman AJ, Winterbottom M, Joy A et al.
Journal of Youth and Adolescence, Springer Nature vol. 52 (2), 331-343.
07-11-2022
Gender Stereotypes and Peer Selection in STEM Domains Among Children and AdolescentsMcGuire L, Hoffman AJ, Mulvey KL, Hartstone-Rose A, Winterbottom M, Joy A, Law F, Balkwill F et al.
Sex Roles, Springer Nature vol. 87 (9-10), 455-470.
01-11-2022
The tumour microenvironment of clear cell ovarian cancerDevlin M-J, Miller R, Laforets F, Kotantaki P, Garsed DW, Kristeleit R, Bowtell DD, McDermott J et al.
Cancer Immunology Research, American Association For Cancer Research (Aacr) vol. 10 (11), 1326-1339.
12-09-2022
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1βOlivera I, Sanz-Pamplona R, Bolaños E, Rodriguez I, Etxeberria I, Cirella A, Egea J, Garasa S et al.
Cancer Discovery, American Association For Cancer Research (Aacr) vol. 12 (9), 2140-2157.
30-06-2022
Abstract 693: TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancerJoy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Hopkins S, Calleja I, Brett S et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (12_Supplement), 693-693.
15-06-2022
Preparing the Next Generation for STEM: Adolescent Profiles Encompassing Math and Science Motivation and Interpersonal Skills and Their Associations With Identity and BelongingMulvey KL, McGuire L, Mathews C, Hoffman AJ, Law F, Joy A, Hartstone-Rose A, Winterbottom M et al.
Youth & Society, Sage Publications vol. 55 (6), 1207-1230.
03-05-2022
Organ-on-a-chip: current gaps and future directionsCandarlioglu PL, Dal Negro G, Hughes D, Balkwill F, Harris K, Screen H, Morgan H, David R et al.
Biochemical Society Transactions, Portland Press vol. 50 (2), 665-673.
19-04-2022
Immune mechanisms of resistance to cediranib in ovarian cancerDifferential response and resistance to cediranib in HGSOCGopinathan G, Berlato C, Lakhani A, Szabova L, Pegrum C, Pedrosa A-R, Laforets F, Maniati E et al.
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr) vol. 21 (6), 1030-1043.
21-03-2022
Building in vitro 3D human multicellular models of high-grade serous ovarian cancerMalacrida B, Pearce OMT, Balkwill FR
Star Protocols, Elsevier vol. 3 (1)
11-01-2022
Harnessing cytokines and chemokines for cancer therapyPropper DJ, Balkwill FR
Nature Reviews Clinical Oncology, Springer Nature vol. 19 (4), 237-253.
07-01-2022
TGFß-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancerJoy JD, Malacrida B, Laforets F, Kotantaki P, Maniati E, Hopkins S, Calleja I, Brett S et al.
01-01-2022
2021
Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon CancerLeonard NA, Reidy E, Thompson K, McDermott E, Peerani E, Bort ET, Balkwill FR, Loessner D et al.
Cancers, Mdpi vol. 13 (23)
29-11-2021
Loss of mTORC2-induced metabolic reprogramming in monocytes uncouples migration and maturation from production of proinflammatory mediatorsJangani M, Vuononvirta J, Yamani L, Ward E, Capasso M, Nadkarni S, Balkwill F, Marelli-Berg F
Journal of Leukocyte Biology, Oxford University Press (Oup) vol. 111 (5), 967-980.
29-09-2021
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian CancerTGFBI and Ovarian CancerLecker LSM, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 81 (22), 5706-5719.
24-09-2021
Impact of Youth and Adult Informal Science Educators on Youth Learning at ExhibitsMcGuire L, Hoffman AJ, Mulvey KL, Winterbottom M, Balkwill F, Burns KP, Chatton M, Drews M et al.
Visitor Studies, Taylor & Francis vol. 25 (1), 41-59.
13-07-2021
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasionMalacrida B, Nichols S, Maniati E, Jones R, Delanie-Smith R, Roozitalab R, Tyler EJ, Thomas M et al.
Iscience, Elsevier vol. 24 (6)
29-05-2021
Modelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancerDelaine-Smith RM, Maniati E, Malacrida B, Nichols S, Roozitalab R, Jones RR, Lecker LSM, Pearce OMT et al.
Iscience, Elsevier vol. 24 (6)
29-05-2021
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian CancerHeath O, Berlato C, Maniati E, Lakhani A, Pegrum C, Kotantaki P, Elorbany S, Böhm S et al.
Cancer Immunology Research, American Association For Cancer Research (Aacr) vol. 9 (6), 665-681.
10-04-2021
Cells are Us – combining research and public engagementBalkwill FR
Nature Reviews Cancer, Springer Nature vol. 21 (5), 277-278.
24-03-2021
Investigating the impact of London’s Ultra Low Emission Zone on children’s health: Children’s Health in London and Luton (CHILL): Protocol for a prospective parallel cohort studyColligan G, Tsocheva I, Scales J, Chavda J, Dove R, Kalsi H, Wood H, Cross L et al.
, Cold Spring Harbor Laboratory
08-02-2021
Modelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancerDelaine-Smith R, Maniati E, Malacrida B, Nichols S, Roozitalab R, Jones R, Lecker L, Pearce O et al.
Biorxiv.Org
02-02-2021
Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in MiceDelvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M et al.
Cellular and Molecular Gastroenterology and Hepatology, Elsevier vol. 12 (5), 1543-1565.
01-01-2021
Using 3-Dimensional in vitro models to unravel the complexity of the metastatic microenvironment in high-grade serous ovarian cancer.Malacrida B, Delaine-Smith R, Nichols S, Maniati E, Jones RL, Knight MM, Pearce OM, Balkwill FR
01-01-2021
2020
Author Correction: A guiding map for inflammationNetea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS et al.
Nature Immunology, Springer Nature vol. 22 (2), 254-254.
07-12-2020
Targeting DNA Damage Response and Replication Stress in Pancreatic CancerDreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki E-M, Dray E, Serrels B, Caligiuri G et al.
Gastroenterology, Elsevier vol. 160 (1), 362-377.e13.
09-10-2020
Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.Mcclelland S, Tamura N, Shaikh N, Muliaditan D, Soliman T, McGuinness J, Maniati E, Moralli D et al.
Cancer Research, American Association For Cancer Research
30-09-2020
The role of the tumour microenvironment in pituitary adenoma angiogenesisMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Mendoza N, Muquit S et al.
Endocrine Abstracts, Bioscientifica
21-08-2020
The Relations and Role of Social Competencies and Belonging with Math and Science Interest and Efficacy for Adolescents in Informal STEM ProgramsHoffman AJ, McGuire L, Rutland A, Hartstone-Rose A, Irvin MJ, Winterbottom M, Balkwill F, Fields GE et al.
Journal of Youth and Adolescence, Springer Nature vol. 50 (2), 314-323.
17-08-2020
Abstract 2217: Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapyPavlyk I, Foster J, Dexter K, Sobasowski J, Bomalarski J, Berlato C, Balkwill F, Szlosarek PW
15-08-2020
Abstract 4976: Combining measures of immune infiltration uncovers predictors of survival in high-grade serous ovarian cancerMontfort A, Owen SJ, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Boehm S, Pharoah P et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 80 (16_Supplement), 4976-4976.
15-08-2020
A Darker Side to Retinoic Acid Revealed by SarcomasBalkwill FR
New England Journal of Medicine, Massachusetts Medical Society vol. 383 (5), 491-493.
30-07-2020
Interest and learning in informal science learning sites: Differences in experiences with different types of educatorsMulvey KL, McGuire L, Hoffman AJ, Goff E, Rutland A, Winterbottom M, Balkwill F, Irvin MJ et al.
Plos One, Public Library of Science (Plos) vol. 15 (7)
23-07-2020
Learning hand in hand: Engaging in research–practice partnerships to advance developmental scienceMulvey KL, McGuire L, Hoffman AJ, Hartstone‐Rose A, Winterbottom M, Balkwill F, Fields GE, Burns K et al.
New Directions For Child and Adolescent Development, Hindawi vol. 2020 (172), 125-134.
01-07-2020
Abstract IA15: Modeling the tumor microenvironment of high-grade serous ovarian cancerBalkwill F
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 26 (13_Supplement), ia15-ia15.
01-07-2020
Airway dendritic cell maturation in children exposed to air pollutionWhitehouse AL, Mushtaq N, Miyashita L, Barratt B, Khan A, Kalsi H, Koh L, Padovan MG et al.
Plos One, Public Library of Science (Plos) vol. 15 (5), e0232040-e0232040.
05-05-2020
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinomaMontfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Böhm S, Pharoah P et al.
British Journal of Cancer, Springer Nature [Academic Journals On Nature.Com]
06-04-2020
Cancer associated fibroblast FAK regulates malignant cell metabolismDemircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, Reynolds LE, Gomez-Escudero J et al.
Nature Communications, Springer Science and Business Media Llc vol. 11 (1)
10-03-2020
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to TreatmentManiati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C et al.
Ssrn Electronic Journal, Elsevier Bv
14-01-2020
Modeling the tumor microenvironment of high-grade serous ovarian cancer.Balkwill F
01-01-2020
2019
Pituitary tumour fibroblast-derived cytokines influence tumour aggressivenessMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J et al.
Endocrine Related Cancer, Bioscientifica vol. -1 (aop), 853-865.
01-12-2019
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumoursMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J et al.
Acta Neuropathologica Communications, Springer Nature vol. 7 (1)
08-11-2019
Abstract 1103: The effects of neo-adjuvant chemotherapy on myeloid cells in high-grade serous ovarian cancer metastasesHeath OM, Maniati E, Belato C, Gopinathan G, Lecker L, Lakhani A, Pegrum C, McDermott J et al.
01-07-2019
Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotypeMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Mendoza N, Dorward N et al.
Endocrine Abstracts, Bioscientifica
01-05-2019
MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on MacrophagesMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J et al.
Journal of The Endocrine Society, The Endocrine Society vol. 3 (Supplement_1), mon-462.
15-04-2019
MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J et al.
Journal of The Endocrine Society, The Endocrine Society vol. 3 (Supplement_1), mon-460.
15-04-2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceBast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL et al.
Cancer vol. 125 (12), 1963-1972.
05-03-2019
Discrepancies in the tumor microenvironment of spontaneous and orthotopic murine models of pancreatic cancer uncover a new immunostimulatory phenotype for B cellsSpear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, Balkwill FR, Kocher HM et al.
Frontiers in Immunology, Frontiers Media vol. 10 (MAR)
01-01-2019
2018
Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using ProteomicsNaba A, Pearce OMT, Del Rosario A, Ma D, Ding H, Rajeeve V, Cutillas PR, Balkwill FR et al.
Journal of Proteome Research vol. 16 (8), 3083-3091.
01-12-2018
Mets and NETs: The Awakening ForceSanz-Moreno V, Balkwill FR
Immunity vol. 49 (5), 798-800.
20-11-2018
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeCandido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A et al.
Cell Reports, Elsevier vol. 23 (5), 1448-1460.
01-05-2018
CytokinesMalik STA, Balkwill FR
In The Nude Mouse in Oncology Research 247-261.
01-01-2018
2017
Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers.Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al.
Cancer Discov
01-12-2017
A guiding map for inflammation.Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS et al.
Nat Immunol vol. 18 (8), 826-831.
19-07-2017
Upregulation of amphiregulin on CD14++CD16- (classical) monocytes in non-small cell lung cancer.McCarthy FM, Candido J, Rudd R, Steele JPC, Balkwill F
20-05-2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancerJournal of Clinical Investigation, American Society For Clinical Investigation
30-01-2017
The Chemokine CXCL10 is a Potential Regulator of Cancer Stem Cells in High Grade Serous CarcinomaMcDermott JR, Jones R, Lockley M, Balkwill FR
01-01-2017
2016
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous CarcinomaWalton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 76 (20), 6118-6129.
13-10-2016
Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal AdenocarcinomaDawkins JBN, Wang J, Maniati E, Heward JA, Koniali L, Kocher HM, Martin SA, Chelala C et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 76 (16), 4861-4871.
14-08-2016
Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanicsDelaine-Smith RM, Burney S, Balkwill FR, Knight MM
Journal of The Mechanical Behavior of Biomedical Materials, Elsevier Bv vol. 60, 401-415.
01-07-2016
A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH et al.
Clinical Cancer Research, American Association For Cancer Research
27-06-2016
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal AdenocarcinomaSteele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S et al.
Cancer Cell, Elsevier (Cell Press) vol. 29 (6), 832-845.
13-06-2016
Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinomaBALKWILL F, Anne Montfort, Oliver Pearce
Clinical Cancer Research, American Association For Cancer Research
01-04-2016
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsKulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M et al.
Oncotarget, Impact Journals vol. 7 (13), 15648-15661.
08-02-2016
Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer.Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 22 (2_Supplement), B53-B53.
15-01-2016
What drives chromosomal instability in high-grade serous ovarian cancer?Tamura N, Shaikh N, McGuinness JR, Bowtell D, Balkwill F, Petermann E, McClelland SE
01-01-2016
2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerBowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, Berek JS, Birrer MJ et al.
Nature Reviews Cancer, Springer Nature vol. 15 (11), 668-679.
23-10-2015
Centre of the Cell: Science Comes to LifeBalkwill F, Chambers K
Plos Biology, Public Library of Science (Plos) vol. 13 (9)
04-09-2015
Interleukin-6 Stimulates Defective AngiogenesisGopinathan G, Milagre C, Pearce OMT, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (15), 3098-3107.
01-08-2015
Abstract 4162: Interleukin–6 stimulates defective angiogenesisGopinathan G, Milagre C, Pearce OMT, Reynolds L, Hodivala-Dilke K, Leinster A, Zhong H, Hollingsworth RE et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (15_Supplement), 4162-4162.
01-08-2015
Abstract 455: B cells actively participate to the anti-cancer immune response in high grade serous ovarian cancer metastasesMontfort A, Boehm S, Dowe T, Topping J, Lockley M, Capasso M, Balkwill F
01-08-2015
Inflammation and cancer: advances and new agentsCrusz SM, Balkwill FR
Nature Reviews Clinical Oncology, Springer Nature vol. 12 (10), 584-596.
30-06-2015
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian CancerMilagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (7), 1255-1264.
31-03-2015
Targeting inflammatory cytokines in cancerBalkwill F
Clinical & Experimental Metastasis vol. 32 (3), 183-183.
01-01-2015
2014
Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer01-10-2014
Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ et al.
Proc Natl Acad Sci U S A vol. 111 (34), E3562-E3570.
26-08-2014
33: Targeting cancer-related inflammationBalkwill F
European Journal of Cancer, Elsevier vol. 50
01-07-2014
Chemotherapy, immunity and microbiota--a new triumvirate?Karin M, Jobin C, Balkwill F
Nat Med vol. 20 (2), 126-127.
01-02-2014
Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.Lau T-S, Chung TK-H, Cheung T-H, Chan LK-Y, Cheung LW-H, Yim S-F, Siu NS-S, Lo K-W et al.
J Pathol vol. 232 (1), 43-56.
01-01-2014
2013
Vaccinia virus induces programmed necrosis in ovarian cancer cells.Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA
Mol Ther vol. 21 (11), 2074-2086.
01-11-2013
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T et al.
Faseb J vol. 27 (10), 4244-4253.
01-10-2013
B regulatory cells in cancer.Balkwill F, Montfort A, Capasso M
Trends Immunol vol. 34 (4), 169-173.
01-04-2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ et al.
Cancer Chemother Pharmacol vol. 71 (4), 1041-1050.
01-04-2013
Major contribution of gamma delta T cells to IL-17A production and ovarian cancer cell growth in vivoRei M, Lanca T, Thompson R, Balkwill F, Silva-Santos B, Pennington DJ
01-01-2013
Tumour-associated inflammatory cytokines are reduced following primary platinum-based chemotherapy in plasma of high-grade serous ovarian cancer patientsBoehm S, Ennis D, Dowe T, Canosa M, McNeish I, Lockley M, Balkwill F
01-01-2013
2012
The tumor microenvironment at a glance.Balkwill FR, Capasso M, Hagemann T
J Cell Sci vol. 125 (Pt 23), 5591-5596.
01-12-2012
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA et al.
Oncogene vol. 31 (48), 4987-4995.
29-11-2012
The peritoneal tumour microenvironment of high‐grade serous ovarian cancerLeinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D et al.
The Journal of Pathology, Wiley vol. 227 (2), 136-145.
18-04-2012
Abstract 4391: CD20 as a target for therapy in solid tumorsAffara NI, Ruffell B, Johansson M, Fujikawa K, Bergsland E, DeNardo DG, Chen HI, Wadhwani N et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 4391-4391.
15-04-2012
Abstract 49: Targeting the TNF network in human ovarian cancer - A systems biology approachKulbe H, Chakravarty P, Moore R, Iorio F, Montoya A, Saez-Rodriguez J, Cutillas P, Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 49-49.
15-04-2012
Paraneoplastic thrombocytosis in ovarian cancer.Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN et al.
N Engl J Med vol. 366 (7), 610-618.
16-02-2012
Cancer-related inflammation: common themes and therapeutic opportunities.Balkwill FR, Mantovani A
Semin Cancer Biol vol. 22 (1), 33-40.
01-02-2012
The chemokine system and cancer.Balkwill FR
J Pathol vol. 226 (2), 148-157.
01-01-2012
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T et al.
Cancer Res vol. 72 (1), 66-75.
01-01-2012
2011
IL-6 and ovarian cancer--response.Balkwill FR, Coward J, Kulbe H, Milagre C, Gopinathan G, McNeish IA
Clin Cancer Res vol. 17 (24)
15-12-2011
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA et al.
J Clin Invest vol. 121 (12), 4685-4699.
01-12-2011
Inflammatory cytokines and autocrine tumour-promoting networksBalkwill F
01-10-2011
Rethinking ovarian cancer: recommendations for improving outcomes.Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC et al.
Nat Rev Cancer vol. 11 (10), 719-725.
23-09-2011
Interleukin-6 as a therapeutic target in human ovarian cancer.Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T et al.
Clin Cancer Res vol. 17 (18), 6083-6096.
15-09-2011
Safety of medicines and the use of animals in research.Balkwill F, Whitehead S, Willis P, Gaymond N, Kent A, Page C, Lovell-Badge R, Morris R et al.
Lancet vol. 378 (9786), 127-128.
09-07-2011
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM et al.
Proc Natl Acad Sci U S A vol. 108 (26), 10662-10667.
28-06-2011
INFLAMMATORY CYTOKINES AND AUTOCRINE TUMOR-PROMOTING NETWORKSBalkwill F
01-06-2011
Translating science in more ways than one: an interview with Frances BalkwillAllan S, Balkwill F
Dis Model Mech vol. 4 (3), 286-288.
01-05-2011
Deciphering the Genetic Predisposition to Primary Sclerosing CholangitisKarlsen T, Kaser A
Seminars in Liver Disease, Thieme vol. 31 (02), 188-207.
01-05-2011
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J et al.
Clin Cancer Res vol. 17 (8), 2538-2548.
15-04-2011
Inhibition of the Inflammatory Cytokine TNF-alpha Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 ExpressionSalako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA
Mol Ther vol. 19 (3), 490-499.
01-03-2011
MECHANISMS OF THE TUMOR-PROMOTING ACTION OF TNF-alpha IN EPITHELIAL TUMORSBalkwill F
01-01-2011
ROLE OF B CELL IN TWO-STAGE SKIN CARCINOGENESISSchioppa T, Moore R, Thompson R, de Visser K, Coussens LM, Balkwill F
01-01-2011
Understanding the dual role of murine γδ T cells in tumour surveillance and tumour progressionRei M, Lanca T, King E, Kulbe H, Balkwill F, Silva-Santos B, Pennington DJ
01-01-2011
Cross-talk between IKK2 and Notch promotes pancreatic cancer progression in mice through Hes1 mediated PPARγ inhibitioManiati E, Bossard M, Cook N, Candido J, Emami-Shahri N, Nedospasov S, Balkwill F, Tuveson D et al.
01-01-2011
2010
TNF: a tumor-suppressing factor or a tumor-promoting factor?Balkwill F, Joffroy C
Future Oncol vol. 6 (12), 1833-1836.
01-12-2010
Inflammatory cytokines and autocrine tumor-promoting networksBalkwill F
01-12-2010
Targeting Inflammatory Pathways in Epithelial Ovarian CancerCoward J, Balkwill F
In Emerging Therapeutic Targets in Ovarian Cancer, Springer Nature 133-164.
23-10-2010
The Inflammatory Tissue Microenvironment and the Early Stages of MalignancyBalkwill F
In Pre-Invasive Disease: Pathogenesis and Clinical Management, Springer Nature 21-29.
26-08-2010
p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarkerFlak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP et al.
Mol Cancer vol. 9
03-07-2010
Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP, Bangham CRM
J Immunol vol. 185 (1), 183-189.
01-07-2010
Guidelines for the welfare and use of animals in cancer research.Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J et al.
Br J Cancer vol. 102 (11), 1555-1577.
25-05-2010
Interleukin-6 as a therapeutic target in advanced ovarian cancer.Coward JI, Kulbe H, Leader D, Quigley M, Thompson R, Leinster A, Nemeth J, Vermeulen J et al.
20-05-2010
Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.Forster MD, Patnaik A, Sandhu SK, Papadopoulos K, Tromp BJ, Messiou C, Balkwill F, Berns B et al.
20-05-2010
Abstract 5331: Interleukin-6 as a therapeutic target in advanced ovarian cancerCoward J, Kulbe H, Leader D, Quigley M, Leinster DA, Thompson R, Nemeth J, Vermeulen J et al.
15-04-2010
Cancer and inflammation: implications for pharmacology and therapeutics.Balkwill F, Mantovani A
Clin Pharmacol Ther vol. 87 (4), 401-406.
01-04-2010
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C et al.
Proc Natl Acad Sci U S A vol. 107 (5), 2177-2182.
02-02-2010
Foreword.Balkwill F, Mantovani A
Cytokine Growth Factor Rev vol. 21 (1)
01-02-2010
2009
Abstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumorsSandhu SK, Fong PC, Patnaik A, Papadopoulos K, Messiou C, Hoare S, Olmos D, Tromp BJ et al.
10-12-2009
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG et al.
J Clin Invest vol. 119 (10), 3011-3023.
01-10-2009
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F
Mol Cancer Ther vol. 8 (7), 1893-1905.
01-07-2009
Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.Kwong J, Chan FL, Wong K-K, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC
Neoplasia vol. 11 (6), 529-541.
01-06-2009
CHEMOKINE RECEPTORS AND INFLAMMATION IN CANCERBalkwill FR
01-05-2009
Tumour necrosis factor and cancer.Balkwill F
Nat Rev Cancer vol. 9 (5), 361-371.
01-05-2009
A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells.Li NF, Kocher HM, Salako MA, Obermueller E, Sandle J, Balkwill F
Oncogene vol. 28 (5), 773-780.
05-02-2009
Spontaneously transformed hTERT immortalized human ovarian surface epithelial cells have a functional amplification of the CXCR4 gene locusArchibald K, Kwong J, Kulbe H, Young B, Balkwill F
Cancer Research vol. 69
01-01-2009
A Phase II study of intravenous CNT0328 in patients with recurrent epithelial ovarian cancerCoward J, Quigley M, Leader D, Berns B, Balkwill F, McNeish I
Cancer Research vol. 69
01-01-2009
Role of B cell in two-stage skin carcinogenesisSchioppa T, Moore R, Thompson R, de Visser K, Coussens L, Balkwill F
Cancer Research vol. 69
01-01-2009
An autocrine cytokine network in ovarian cancer that influences patient survivalKulbe H, Leinster A, Chakravarty P, Kwong J, Thompson R, Schioppa T, Coward J, Hagemann T et al.
01-01-2009
2008
The in£ammatory cytokine network of epithelial cancer: Therapeutic implicationsSzlosarek P, Balkwill F
In Cancer and Inflammation 227-240.
07-10-2008
Cancer-related inflammation.Mantovani A, Allavena P, Sica A, Balkwill F
Nature vol. 454 (7203), 436-444.
24-07-2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerBrown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U et al.
Ann Oncol vol. 19 (7), 1340-1346.
01-07-2008
Re-educating tumor-associated macrophages by targeting NF-kappaB.Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR
J Exp Med vol. 205 (6), 1261-1268.
09-06-2008
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN et al.
Gynecol Oncol vol. 108 (3), 652-657.
01-03-2008
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cellsKaragiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N et al.
Cancer Immunol Immun vol. 57 (2), 247-263.
01-02-2008
2007
Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high doseHarrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K et al.
10-10-2007
Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I et al.
Cell Prolif vol. 40 (5), 780-794.
01-10-2007
Inflammation and cancer: A double-edged swordHagemann T, Balkwill F, Lawrence T
Cancer Cell vol. 12 (4), 300-301.
01-10-2007
IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cellsKaragiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG et al.
J Immunol vol. 179 (5), 2832-2843.
01-09-2007
Cancer. Sex, cytokines, and cancer.Lawrence T, Hageman T, Balkwill F
Science vol. 317 (5834), 51-52.
06-07-2007
Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G, Balkwill FR
Int J Cancer vol. 121 (1), 6-11.
01-07-2007
Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR
Mol Cancer Ther vol. 6 (7), 1993-2002.
01-07-2007
The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cellsKulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A et al.
Cancer Res vol. 67 (2), 585-592.
15-01-2007
IKKbeta inhibits 'Classical' macrophage activation in innate immunity and cancerLawrence T, Fong C, Bebien M, Karin M, Balkwill F, Hagemann T
01-01-2007
2006
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletionSzlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP et al.
Clin Cancer Res vol. 12 (23), 7126-7131.
01-12-2006
RaIB signaling: A bridge between inflammation and cancerMantovani A, Balkwill F
Cell vol. 127 (1), 42-44.
06-10-2006
Bone marrow contributes to functionally active cells in tumour stromaDirekze NC, Jeffery R, Hodivala-Dilke K, Burke F, Hunt FT, Poulsom R, Balkwill F, Wright NA et al.
01-09-2006
TNF-alpha in promotion and progression of cancer.Balkwill F
Cancer Metastasis Rev vol. 25 (3), 409-416.
01-09-2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A et al.
J Clin Oncol vol. 24 (13), 2105-2112.
01-05-2006
Ovarian cancer cells polarize macrophages towards a tumor-associated phenotypeHagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S et al.
Med Klin vol. 101 (4), A44-A44.
15-04-2006
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S et al.
J Immunol vol. 176 (8), 5023-5032.
15-04-2006
Cancer and inflammationBalkwill F
Eur J Cancer vol. 42 (6), 689-690.
01-04-2006
Tumour necrosis factor-alpha as a tumour promoter.Szlosarek P, Charles KA, Balkwill FR
Eur J Cancer vol. 42 (6), 745-750.
01-04-2006
10th Biennial Helene Harris Memorial Trust meeting.Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME et al.
Cancer Res vol. 66 (6), 2904-2906.
15-03-2006
Inflammation: a double-edged swordBalkwill F
Eur J Cancer vol. 42 (5), 571-571.
01-03-2006
Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epitheliumSzlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR
Mol Cancer Ther vol. 5 (2), 382-390.
01-02-2006
2005
Book ReviewBalkwill F
New England Journal of Medicine, Massachusetts Medical Society vol. 353 (22), 2413-2414.
01-12-2005
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cellsKulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL
Cancer Res vol. 65 (22), 10355-10362.
15-11-2005
MIFed about cancer?Hagemann T, Balkwill F
Gastroenterology vol. 129 (5), 1785-1787.
01-11-2005
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F et al.
J Clin Oncol vol. 23 (25), 5950-5959.
01-09-2005
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T et al.
J Immunol vol. 175 (2), 1197-1205.
15-07-2005
Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin.Barton C, Davies D, Balkwill F, Burke F
Eur J Cancer vol. 41 (10), 1474-1486.
01-07-2005
The language of life: How cells communicate in health and diseaseBalkwill F
Nature vol. 435 (7046), 1162-1162.
30-06-2005
Immunology for the next generation.Balkwill F
Nat Rev Immunol vol. 5 (6), 509-512.
01-06-2005
Bortezomib (VELCADE (R)) in patients with relapsed/refractory lymphoma: Potential correlation of TNF alpha response and in vitro sensitivity with clinical activityStrauss S, Maharaj L, Hoare S, Trehu E, Boral A, Schenkein D, Johnson P, Balkwill F et al.
01-06-2005
Fran Balkwill.Balkwill F, Watt F
J Cell Sci vol. 118 (Pt 7), 1339-1340.
01-04-2005
Bone marrow contributes functionally active cell types to tumour stromaDirekze N, Jeffery R, Hodivala-Dilke K, Burke F, Hunt T, Poulsom R, Alison M, Balkwill F et al.
01-04-2005
Bone marrow contributes to functionally active cells in tumour stromaDirekze NC, Jeffery R, Hodivala-Dilke K, Burke F, Hunt FT, Poulsom R, Alison MR, Balkwill F et al.
01-04-2005
Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseBalkwill F, Charles KA, Mantovani A
Cancer Cell vol. 7 (3), 211-217.
01-03-2005
2004
DiscussionOppenheim J, Blankenstein T, Brennan F, Gordon S, Mantovani A, Strieter RM, Cerundolo V, Forni G et al.
01-12-2004
Final general discussionD'Incalci M, Strieter RM, Mantovani A, Balkwill F, Ristimäki A, Pepper MS, Gordon S, Pollard JW
01-12-2004
General discussion ISmyth J, Rollins B, Harris A, Richmond A, Oppenheim J, Feldmann M, Ristimäki A, Pepper MS et al.
01-12-2004
The inflammatory cytokine network and the development of epithelial cancer.Balkwill FR
01-11-2004
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S et al.
Clin Cancer Res vol. 10 (19), 6528-6534.
01-10-2004
Cancer - An inflammatory linkBalkwill F, Coussens LM
Nature vol. 431 (7007), 405-406.
23-09-2004
TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?Scott KA, Arnott CH, Robinson SC, Moore RJ, Thompson RG, Marshall JF, Balkwill FR
Oncogene vol. 23 (41), 6954-6966.
09-09-2004
213 A Phase Ii Study of Etanercept (ENBREL), A Tumour Necrosis Factor-Alpha Inhibitor in Recurrent Ovarian CancerMadhusudan S, Muthuramalingam SR, Braybrooke J, Wilner S, Kaur K, Han C, Hoare S, Balkwill F et al.
International Journal of Gynecological Cancer, Elsevier vol. 14, 61-62.
01-09-2004
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C
Carcinogenesis vol. 25 (8), 1543-1549.
01-08-2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S et al.
Br J Cancer vol. 91 (1), 30-36.
05-07-2004
Cancer and the chemokine networkBalkwill F
Nat Rev Cancer vol. 4 (7), 540-550.
01-07-2004
Regulation and expression of argininosuccinate synthetase in human ovarian cancerSzlosarek PW, Grimshaw MJ, Wilbanks GD, Burke F, Wilson JL, Balkwill FR
01-07-2004
Transfection of the chemokine receptor CXCR4 alters the behavior of ovarian cancer cells in vitro and in vivoKulbe H, Wilson JL, Balkwill FR
01-07-2004
A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro.Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D, Gayther SA
Lab Invest vol. 84 (7), 923-931.
01-07-2004
Establishing cellular model for studying the carcinogenesis of human ovarian epitheliumLi N, Wilbanks G, Dafou D, Jacobs I, Balkwill F, Gayther S
01-07-2004
The significance of cancer cell expression of the chemokine receptor CXCR4Balkwill F
Semin Cancer Biol vol. 14 (3), 171-179.
01-06-2004
A role for endothelin-2 and its receptors in breast tumor cell invasion.Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR
Cancer Res vol. 64 (7), 2461-2468.
01-04-2004
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development.Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR
Oncogene vol. 23 (10), 1902-1910.
11-03-2004
Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003)Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G et al.
Eur J Cancer vol. 40 (4), 628-628.
01-03-2004
The chemokine network in cancer - much more than directing cell movementKulbe H, Levinson NR, Balkwill F, Wilson JL
Int J Dev Biol vol. 48 (5-6), 489-496.
01-01-2004
The inflammatory cytokine network of epithelial cancer: therapeutic implications.Szlosarek P, Balkwill F
Novartis Found Symp vol. 256, 227-237.
01-01-2004
2003
A phase II Trial of etanercept a recombinant human soluble tumour necrosis factor receptor (p75) fusion protein in patients with metastatic breast cancer.Madhusudan S, Braybrooke JP, Forster M, Wilner S, Han C, Kaur K, Balkwill F, Hoare S et al.
01-12-2003
Expression of both TNFR1 and TNFR2 is essential for optimal TNF-alpha-mediated skin tumor development.Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, East N, Balkwill FR
01-12-2003
A chemokine receptor antagonist inhibits experimental breast tumor growth.Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill FR
Cancer Res vol. 63 (23), 8360-8365.
01-12-2003
Inhibiting inflammatory cytokines and chemokines in the tumour microenvironmentBalkwill F
01-11-2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancerMadhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P et al.
Brit J Cancer vol. 89 (8), 1418-1422.
20-10-2003
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G et al.
Eur J Cancer vol. 39 (13), 1818-1827.
01-09-2003
Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.Szlosarek PW, Balkwill FR
Lancet Oncol vol. 4 (9), 565-573.
01-09-2003
A phase II trial of etanercept, a tumour necrosis factor-alpha inhibitor in recurrent ovarian cancerRamalingam S, Hoare S, Madhusudan S, Braybrooke J, Kaur K, Willner S, Harris AL, Balkwill F et al.
01-07-2003
IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.Wall L, Burke F, Barton C, Smyth J, Balkwill F
Clin Cancer Res vol. 9 (7), 2487-2496.
01-07-2003
IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitroWall L, Burke F, Barton C, Smyth J, Balkwill F
Clinical Cancer Research vol. 9 (7), 2487-2496.
01-07-2003
An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR
Mol Cancer Ther vol. 2 (5), 445-451.
01-05-2003
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cellsKaragiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR et al.
Eur J Immunol vol. 33 (4), 1030-1040.
01-04-2003
Chemokine biology in cancerBalkwill F
Semin Immunol vol. 15 (1), 49-55.
01-02-2003
The anti-proliferative activity of interferon-gamma on ovarian cancer: In vitro and in vivoWall L, Burke F, Smyth JF, Balkwill F
01-01-2003
The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo.Wall L, Burke F, Smyth JF, Balkwill F
Gynecologic Oncology vol. 88 (1 Pt 2)
01-01-2003
Discussion: Immunological therapeutics in ovarian cancerBalkwill F, Schlom J, Berek J, Epenetos A, Bookman M, Freedman R, Wilbanks G
01-01-2003
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanomaPropper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N et al.
Clin Cancer Res vol. 9 (1), 84-92.
01-01-2003
2002
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.Grimshaw MJ, Naylor S, Balkwill FR
Mol Cancer Ther vol. 1 (14), 1273-1281.
01-12-2002
A phase II trial of etanercept, a tumour necrosis factor-a inhibitor in recurrent ovarian cancerGanesan T, Madhusudan S, Braybrooke J, Echeta C, Wilner S, Harris AL, Hoare S, Balkwill F
01-11-2002
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancerScotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR
Cancer Res vol. 62 (20), 5930-5938.
15-10-2002
Endothelin-2 is a macrophage chemoattractant: Implications for macrophage distribution in tumorsGrimshaw MJ, Wilson JL, Balkwill FR
European Journal of Immunology vol. 32 (9), 2393-2400.
01-09-2002
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumorsGrimshaw MJ, Wilson JL, Balkwill FR
Eur J Immunol vol. 32 (9), 2393-2400.
01-09-2002
Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway.Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, Balkwill FR, Owens DM
Oncogene vol. 21 (31), 4728-4738.
18-07-2002
Cytokines and infections: good, bad and effective therapies?Balkwill F
Trends in Immunology, Elsevier vol. 23 (7)
01-07-2002
A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancerForster MD, Braybrooke J, Madhusudan S, Kaur K, Hoare S, Balkwill F, Ganesan TS, Talbot D et al.
Brit J Cancer vol. 86, S38-S38.
01-06-2002
Characterisation of the cell content of malignant ascites in advanced epithelial ovarian cancer and clinico-pathological correlationsWall L, Burke F, Smyth J, Balkwill F
Brit J Cancer vol. 86, S45-S46.
01-06-2002
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascitesMilliken D, Scotton C, Raju S, Balkwill F, Wilson J
Clin Cancer Res vol. 8 (4), 1108-1114.
01-04-2002
Tumor necrosis factor or tumor promoting factor?Balkwill F
Cytokine Growth Factor Rev vol. 13 (2), 135-141.
01-04-2002
The role of cytokines in the epithelial cancer microenvironmentWilson J, Balkwill F
Semin Cancer Biol vol. 12 (2), 113-120.
01-04-2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-αRobinson SC, Scott KA, Balkwill FR
European Journal of Immunology vol. 32 (2), 404-412.
07-03-2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha.Robinson SC, Scott KA, Balkwill FR
Eur J Immunol vol. 32 (2), 404-412.
01-02-2002
2001
Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.Scotton C, Milliken D, Wilson J, Raju S, Balkwill F
Br J Cancer vol. 85 (6), 891-897.
14-09-2001
Epithelial cancer cell migration: a role for chemokine receptors?Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR
Cancer Res vol. 61 (13), 4961-4965.
01-07-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanismGrimsha MJ, Balkwill FR
Brit J Cancer vol. 85, 19-19.
01-07-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanismGrimshaw MJ, Balkwill FR
European Journal of Immunology vol. 31 (2), 480-489.
03-03-2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P et al.
J Clin Oncol vol. 19 (5), 1485-1492.
01-03-2001
Inflammation and cancer: back to Virchow?Balkwill F, Mantovani A
Lancet vol. 357 (9255), 539-545.
17-02-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanismGrimshaw MJ, Balkwill FR
Eur J Immunol vol. 31 (2), 480-489.
01-02-2001
2000
Barrett's metaplasiaJankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C
Lancet vol. 356 (9247), 2079-2085.
16-12-2000
Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer modelScott KA, Holdsworth H, Balkwill FR, Dias S
British Journal of Cancer, Springer Nature vol. 83 (11), 1538-1543.
14-11-2000
TNF is here to stay!Balkwill F, Foxwell B, Brennan F, Balkwill F, Foxwell B, Brennan F
01-10-2000
Re: Possible Role of Ovarian Epithelial Inflammation in Ovarian CancerBalkwill FR
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 92 (2), 162a-1163.
19-01-2000
Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian CarcinomaSica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei F, LaRosa G et al.
The Journal of Immunology, Oxford University Press (Oup) vol. 164 (2), 733-738.
15-01-2000
1999
TNF biosynthesis in gut associated immunopathologiesBalkwill F
Gut, Bmj vol. 45 (4)
01-10-1999
Erratum to “Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis”Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L et al.
Nature Medicine, Springer Nature vol. 5 (9), 1087-1087.
01-09-1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F et al.
Cancer Research vol. 59 (16), 3980-3984.
15-08-1999
Hypoxia inhibits macrophage migrationTurner L, Scotton C, Negus R, Balkwill F
European Journal of Immunology vol. 29 (7), 2280-2287.
17-07-1999
Hypoxia inhibits macrophage migrationTurner L, Scotton C, Negus R, Balkwill F
European Journal of Immunology, Wiley vol. 29 (7), 2280-2287.
01-07-1999
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesisMoore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L et al.
Nature Medicine, Springer Nature vol. 5 (7), 828-831.
01-07-1999
Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNABurke F, Smith PD, Crompton MR, Upton C, Balkwill FR
British Journal of Cancer, Springer Nature vol. 80 (8), 1236-1244.
28-05-1999
MMP-2 release and activation in ovarian carcinoma: the role of fibroblastsBoyd RS, Balkwill FR
British Journal of Cancer, Springer Nature vol. 80 (3-4), 315-321.
09-04-1999
1998
IL‐12 regulates VEGF and MMPs in a murine breast cancer modelDias S, Boyd R, Balkwill F
International Journal of Cancer, Wiley vol. 78 (3), 361-365.
29-10-1998
IL-12 regulates VEGF and MMPs in a murine breast cancer modelDias S, Boyd R, Balkwill F
International Journal of Cancer vol. 78 (3), 361-365.
29-10-1998
Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF)Leber T, Balkwill F
British Journal of Cancer, Springer Nature vol. 78 (6), 724-732.
01-09-1998
Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumorsNegus RPM, Turner L, Burke F, Balkwill FR
Journal of Leukocyte Biology, Oxford University Press (Oup) vol. 63 (6), 758-765.
01-06-1998
Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer modelDias S, Thomas H, Balkwill F
International Journal of Cancer, Wiley vol. 75 (1), 151-157.
05-01-1998
Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer modelDias S, Thomas H, Balkwill F
International Journal of Cancer vol. 75 (1), 151-157.
05-01-1998
The molecular and cellular biology of the chemokinesBalkwill F
Journal of Viral Hepatitis, Wiley vol. 5 (1), 1-14.
01-01-1998
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)British Journal of Cancer, Springer Nature vol. 77 (1), 1-10.
01-01-1998
1997
Cytokine amplification and inhibition of immune and inflammatory responsesBalkwill F
Journal of Viral Hepatitis, Wiley vol. 4 (s2), 6-15.
01-11-1997
Zymography: A Single-Step Staining Method for Quantitation of Proteolytic Activity on Substrate GelsLeber TM, Balkwill FR
Analytical Biochemistry, Elsevier vol. 249 (1), 24-28.
01-06-1997
Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastatBurke F, East N, Upton C, Patel K, Balkwill FR
, Elsevier vol. 33 (7), 1114-1121.
01-06-1997
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.Negus RP, Stamp GW, Hadley J, Balkwill FR
American Journal of Pathology vol. 150 (5), 1723-1734.
01-05-1997
Interferons and cytokines on a grand scaleBalkwill F, Pitha PM
01-03-1997
1996
Cytokines in animal models of cancerBurke F, Balkwill FR
Biotherapy, Springer Nature vol. 8 (3-4), 229-241.
01-09-1996
Correspondence re: N-B. Liabakk et al., matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1966.Zucker S
Cancer Research vol. 56 (15)
01-08-1996
A CYTOKINE PROFILE OF NORMAL AND MALIGNANT OVARYBurke F, Relf M, Negus R, Balkwill F
Cytokine, Elsevier vol. 8 (7), 578-585.
01-07-1996
Cytokines in tumour growth, migration and metastasisNegus RPM, Balkwill FR
World Journal of Urology, Springer Nature vol. 14 (3), 157-165.
01-06-1996
Cytokines in Hemopoiesis, Oncology, and Immunology IIIBalkwill FR
British Journal of Cancer, Springer Nature vol. 73 (5), 711-711.
01-03-1996
Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer.Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F
Cancer Research vol. 56 (1), 190-196.
01-01-1996
An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic modelThomas H, Hanby A, Smith R-A, Hagger P, Patel K, Raikundalia B, Camplejohn R, Balkwill F
British Journal of Cancer, Springer Nature vol. 73 (1), 65-72.
01-01-1996
1995
Making senseBalkwill F
Nature, Springer Nature vol. 378 (6554), 318-318.
16-11-1995
Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosisde Kossodo S, Moore R, Gschmeissner S, East N, Upton C, Balkwill F
British Journal of Cancer, Springer Nature vol. 72 (5), 1165-1172.
01-11-1995
Assessing new anti-tumour agents and strategies in oncogene transgenic miceThomas H, Balkwill F
Cancer and Metastasis Reviews, Springer Nature vol. 14 (2), 91-95.
01-06-1995
Inhibitory cytokines and cytokine inhibitorsBurger D, Dayer J-M
Neurology, Wolters Kluwer vol. 45 (6), s39-s43.
01-06-1995
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S et al.
Journal of Clinical Investigation, American Society For Clinical Investigation vol. 95 (5), 2391-2396.
01-05-1995
THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivoBurke F, Knowles RG, East N, Balkwill FR
International Journal of Cancer, Wiley vol. 60 (1), 115-122.
03-01-1995
Multiple myeloma: An immunoclinical study of disease and response to treatmentThavasu PW, Ganjoo RK, Maidment SA, Love SB, Williams AH, Malplas JS, Balkwill FR
Hematological Oncology, Wiley vol. 13 (2), 69-82.
01-01-1995
Tumour necrosis factor in ovarian cancerBalkwill F
Interferons and Cytokines (26), 6-8.
01-01-1995
1994
Expression and activity of MMPS and their regulators in ovarian cancerNaylor MS, Stamp GW, Davies BD, Balkwill FR
International Journal of Cancer, Wiley vol. 58 (1), 50-56.
01-07-1994
Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin‐2MILES D, THOMSEN L, BALKWILL F, THAVASU P, MONCADA S
European Journal of Clinical Investigation, Wiley vol. 24 (4), 287-290.
01-04-1994
Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissueMiles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwwill FR
International Journal of Cancer, Wiley vol. 56 (6), 777-782.
15-03-1994
Cytokine therapy of cancer. The importance of knowing the context.Balkwill FR
European Cytokine Network vol. 5 (4), 379-385.
01-01-1994
Oncogene transgenic mice as therapeutic models in cancer researchThomas H, Balkwill FR
, Elsevier vol. 30 (4), 533-537.
01-01-1994
1993
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In VivoPhilip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T et al.
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 85 (22), 1812-1818.
17-11-1993
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D et al.
Cancer Research vol. 53 (22), 5365-5369.
15-11-1993
Activity of type IV collagenases in benign and malignant breast diseaseDavies B, Miles D, Happerfield L, Naylor M, Bobrow L, Rubens R, Balkwill F
British Journal of Cancer, Springer Nature vol. 67 (5), 1126-1131.
01-05-1993
A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR
Cancer Research vol. 53 (9), 2087-2091.
01-05-1993
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR
Journal of Clinical Investigation, American Society For Clinical Investigation vol. 91 (5), 2194-2206.
01-05-1993
Fusion potential for vaccinesTaylor-Papadimitriou J, Balkwill F
Nature, Springer Nature vol. 362 (6422), 695-695.
22-04-1993
The cytokine wall chartBurke F, Naylor MS, Davies B, Balkwill F
Trends in Immunology, Elsevier vol. 14 (4)
01-04-1993
Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expressionSaraya K, Balkwill F
British Journal of Cancer, Springer Nature vol. 67 (3), 514-521.
01-03-1993
Cytokines in health and diseaseBalkwill F
Immunology Today vol. 14 (4), 149-150.
01-01-1993
The cytokine wall chartBurke F, Stuart Naylor M, Davies B, Balkwill F
Immunology Today vol. 14 (4)
01-01-1993
The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemiaBurke F, Griffin D, Elwood N, Davis C, Stamp G, Rohatiner A, Lister TA, Balkwill F
Hematological Oncology, Wiley vol. 11 (1), 23-33.
01-01-1993
1992
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2Miles D, Aderka D, Engelmann H, Wallach D, Balkwill F
British Journal of Cancer, Springer Nature vol. 66 (6), 1195-1199.
01-12-1992
Measuring cytokine levels in blood Importance of anticoagulants, processing, and storage conditionsThavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR
Journal of Immunological Methods, Elsevier vol. 153 (1-2), 115-124.
01-08-1992
Beta actin expression and organization of actin filaments in colorectal neoplasia.Naylor MS, Stamp GW, Balkwill FR
Epithelial Cell Biology vol. 1 (3), 99-104.
01-07-1992
Effects of intraperitoneal recombinant interleukin-1 β in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factorMalik ST, East N, Boraschi D, Balkwill F
British Journal of Cancer, Springer Nature vol. 65 (5), 661-666.
01-05-1992
Tumour necrosis factor and cancerBalkwill FR
Cytokine & Growth Factor Reviews, Elsevier vol. 4 (2), 121-137.
01-01-1992
Antiproliferative and antitumor activity of TNF in vitro and in vivo.Malik ST, Balkwill FR
Immunology Series vol. 56, 239-268.
01-01-1992
1991
Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer.Malik ST, Knowles RG, East N, Lando D, Stamp G, Balkwill FR
Cancer Research vol. 51 (24), 6643-6649.
15-12-1991
Effects of interferons and other cytokines on tumors in animals: A reviewThomas H, Balkwill FR
Pharmacology & Therapeutics, Elsevier vol. 52 (3), 307-330.
01-12-1991
Toxicity and reconstitution of recombinant interleukin-2 with albuminMiles DW, Longhurst SJ, Harper PG, Balkwill FR
The Lancet, Elsevier vol. 338 (8780)
01-12-1991
Epithelial ovarian cancer: a cytokine propelled disease?Malik S, Balkwill F
British Journal of Cancer, Springer Nature vol. 64 (4), 617-620.
01-10-1991
Enhancement of metastatic potential by gamma-interferon.Kelly SA, Gschmeissner S, East N, Balkwill FR
Cancer Research vol. 51 (15), 4020-4027.
01-08-1991
Differential effects of recombinant interferon α on constitutive and inducible cytochrome P450 isozymes in mouse liverStanley LA, Adams DJ, Balkwill FR, Griffin D, Wolf CR
Biochemical Pharmacology, Elsevier vol. 42 (2), 311-320.
01-07-1991
Human small‐cell lung‐cancer cells are cytokine‐resistant but NK/LAK‐sensitiveLagadec PF, Saraya KA, Balkwill FR
International Journal of Cancer, Wiley vol. 48 (2), 311-317.
10-05-1991
Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSFMalik S, Martin D, Hart I, Balkwill F
British Journal of Cancer, Springer Nature vol. 63 (3), 399-403.
01-03-1991
1990
Investigation of cytokine gene expression in human colorectal cancer.Naylor MS, Stamp GW, Balkwill FR
Cancer Research vol. 50 (14), 4436-4440.
15-07-1990
Reconstitution of interleukin 2 with albumin for infusionMiles D, Bird C, Wadhwa M, Summerhayes M, Balkwill F, Thorpe R, Rubens R
The Lancet, Elsevier vol. 335 (8705), 1602-1603.
01-06-1990
In situ detection of tumour necrosis factor in human ovarian cancer specimensNaylor MS, Malik STA, Stamp GWH, Jobling T, Balkwill FR
, Elsevier vol. 26 (10), 1027-1030.
01-01-1990
Cells secreting tumour necrosis factor show enhanced metastasis in nude miceMalik STA, Naylor MS, East N, Oliff A, Balkwill FR
, Elsevier vol. 26 (10), 1031-1034.
01-01-1990
Tumour necrosis factor as an anticancer agentBalkwill FR, Naylor MS, Malik S
, Elsevier vol. 26 (5), 641-644.
01-01-1990
The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models.Malik ST, Griffin DB, Naylor MS, Fiers W, Oliff A, Balkwill FR
Progress in Clinical and Biological Research vol. 349, 393-403.
01-01-1990
1989
Paradoxical effects of tumour necrosis factor in experimental ovarian cancerMalik STA, Griffin DB, Fiers W, Balkwill FR
International Journal of Cancer, Wiley vol. 44 (5), 918-925.
15-11-1989
Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivoBalkwill FR, Griffin DB, Lee AE
, Elsevier vol. 25 (10), 1481-1486.
01-10-1989
The cytokine networkBalkwill FR, Burke F
Trends in Immunology, Elsevier vol. 10 (9), 299-304.
01-09-1989
Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude miceStebbings WSL, Vinson GP, Farthing MJG, Balkwill F, Wood RFM
Journal of Cancer Research and Clinical Oncology, Springer Nature vol. 115 (5), 439-444.
01-09-1989
INTERFERONSBalkwill F
The Lancet, Elsevier vol. 333 (8646), 1060-1063.
01-05-1989
Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine modelRamani P, Balkwill FR
International Journal of Cancer, Wiley vol. 43 (1), 140-146.
15-01-1989
Tumour necrosis factorBalkwill FR
British Medical Bulletin, Oxford University Press (Oup) vol. 45 (2), 389-400.
01-01-1989
Future prospects and problems.Fiers W, Balkwill FR
Cancer Surveys vol. 8 (4), 921-927.
01-01-1989
The relevance of animal tumour models to the preclinical screening of cytokines.Kelly SA, Malik ST, Balkwill FR
Cancer Surveys vol. 8 (4), 741-754.
01-01-1989
1988
Cytokines — soluble factors in immune responsesBalkwill F
Current Opinion in Immunology, Elsevier vol. 1 (2), 241-249.
01-12-1988
Human interferons inhibit experimental metastases of a human melanoma cell line in nude miceRamani P, Balkwill F
British Journal of Cancer, Springer Nature vol. 58 (3), 350-354.
01-09-1988
An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancerFentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF
, Elsevier vol. 24 (8), 1299-1303.
01-08-1988
Tumour necrosis factorMalik S, Balkwill FR
The Bmj, Bmj vol. 296 (6631)
30-04-1988
The anti-cancer activity of tumour necrosis factor.Malik S, Balkwill F
Research in Immunology vol. 139 (3), 285-288.
01-01-1988
1987
Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gammaRamani P, Balkwill FR
International Journal of Cancer, Wiley vol. 40 (6), 830-834.
15-12-1987
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCERBalkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H, Fiers W
The Lancet, Elsevier vol. 330 (8570), 1229-1232.
01-11-1987
2′,5′-Oligoadenylate Synthetase and Interferon in Peripheral Blood after Rubella, Measles, or Mumps Live Virus VaccineTilles JG, Balkwill F, Davilla J
Experimental Biology and Medicine, Frontiers vol. 186 (1), 70-74.
01-10-1987
A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence.Fentiman IS, Balkwill FR, Cuzick J, Hayward JL, Rubens RD
European Journal of Surgical Oncology vol. 13 (5), 425-428.
01-10-1987
Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer.Balkwill FR, Ward BG, Moodie E, Fiers W
Cancer Research vol. 47 (18), 4755-4758.
15-09-1987
INTERFERONS IN CANCER THERAPY: A REAPPRAISALBalkwill FR, Smyth JF
The Lancet, Elsevier vol. 330 (8554), 317-319.
01-08-1987
Interferons in oncology: Current status and future directionsSmyth JF, Balkwill FR, Cavalli F, Kimchi A, Mattson K, Niederle NE, Spiegel RJ
, Elsevier vol. 23 (6), 887-889.
01-06-1987
The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cellsDealtry GB, Naylor MS, Fiers W, Balkwill FR
Experimental Cell Research, Elsevier vol. 170 (2), 428-438.
01-06-1987
Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice.Ward BG, Wallace K, Shepherd JH, Balkwill FR
Cancer Research vol. 47 (10), 2662-2667.
15-05-1987
Induction and suppression of glutathione transferases by interferon in the mouse.Adams DJ, Balkwill FR, Griffin DB, Hayes JD, Lewis AD, Wolf CR
Journal of Biological Chemistry, Elsevier vol. 262 (10), 4888-4892.
01-04-1987
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon‐γDealtry GB, Naylor MS, Fiers W, Balkwill FR
European Journal of Immunology, Wiley vol. 17 (5), 689-693.
01-01-1987
Effects of Tumour Necrosis Factor on Human Tumour Xenografts in Nude MiceBalkwill FR, Ward BG, Fiers W
Novartis Foundation Symposia, Wiley vol. 131, 154-169.
01-01-1987
Interferon gamma regulates HLA-D expression on solid tumors in vivoBalkwill FR, Stevens MH, Griffin DB, Thomas JA, Bodmer JG
, Elsevier vol. 23 (1), 101-106.
01-01-1987
1986
Enhancement by gamma-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen.Rowlinson G, Balkwill F, Snook D, Hooker G, Epenetos AA
Cancer Research vol. 46 (12 Pt 1), 6413-6417.
01-12-1986
Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR, Smyth JF
Cancer Research vol. 46 (10), 4916-4920.
01-10-1986
Effects of mouse interferon on human tumour xenografts in the nude mouse hostBalkwill FR, Proietti E
International Journal of Cancer, Wiley vol. 38 (3), 375-380.
15-09-1986
Interferons: from molecular biology to man. Part 3. Interferons and disease.Balkwill FR
Microbiological Sciences vol. 3 (9), 281-284.
01-09-1986
Interferons: from molecular biology to man. Part 2. Interferons and cell function.Balkwill FR
Microbiological Sciences vol. 3 (8), 229-233.
01-08-1986
Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W
Cancer Research vol. 46 (8), 3990-3993.
01-08-1986
Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system.Balkwill FR
Microbiological Sciences vol. 3 (7), 212-215.
01-07-1986
The effect of interferon on experimental metastases in immunocompetent and immunodeficient miceRamani P, Hart IR, Balkwill FR
International Journal of Cancer, Wiley vol. 37 (4), 563-568.
15-04-1986
[85] Animal models for investigating antitumor effects of interferonBalkwill FR
Methods in Enzymology, Elsevier vol. 119, 649-657.
01-01-1986
1985
Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are dissociableTaylor-Papadimitriou J, Balkwill F, Ebsworth N, Rozengurt E
Virology, Elsevier vol. 147 (2), 405-412.
01-12-1985
Differential action of six human interferons against two human carcinomas growing in nude miceBalkwill FR, Goldstein L, Stebbing N
International Journal of Cancer, Wiley vol. 35 (5), 613-617.
15-05-1985
PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCERFentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL
The Lancet, Elsevier vol. 325 (8438)
01-05-1985
USE OF INTERFERON IN THE MANAGEMENT OF PATIENTS WITH SUBACUTE SCLEROSING PANENCEPHALITISBye A, Balkwill F, Brigden D, Wilson J
Developmental Medicine & Child Neurology, Wiley vol. 27 (2), 170-175.
01-04-1985
Central Nervous System Toxicity of InterferonRohatiner AZS, Prior P, Burton A, Balkwill F, Lister TA
Progress in Tumor Research, Karger Publishers vol. 29, 197-202.
01-01-1985
Recombinant DNA human interferon alpha 2 in advanced breast cancer: A phase 2 trialPadmanabhan N, Balkwill FR, Bodmer JG, Rubens RD
British Journal of Cancer, Springer Nature vol. 51 (1), 55-60.
01-01-1985
1984
Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers.Shearer M, Taylor-Papadimitriou J, Griffin D, Balkwill F
The Journal of Immunology, Oxford University Press (Oup) vol. 133 (6), 3096-3101.
01-12-1984
Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes.Balkwill FR, Mowshowitz S, Seilman SS, Moodie EM, Griffin DB, Fantes KH, Wolf CR
Cancer Research vol. 44 (11), 5249-5255.
01-11-1984
Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycleBalkwill FR, Bokhon'ko AI
Experimental Cell Research, Elsevier vol. 155 (1), 190-197.
01-11-1984
Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system.Balkwill FR, Moodie EM
Cancer Research vol. 44 (3), 904-908.
01-03-1984
Preclinical and clinical studies of interferons and interferon inducers in breast cancerBorden EC, Balkwill FR
Cancer, Wiley vol. 53 (S3), 783-789.
01-02-1984
Preclinical and clinical studies of interferons and interferon inducers in breast cancerBorden EC, Balkwill FR
Cancer vol. 53 (3 S), 783-789.
01-01-1984
1983
Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML)Rohatiner AZS, Balkwill FR, Malpas JS, Lister TA
Cancer Chemotherapy and Pharmacology, Springer Nature vol. 11 (1), 56-58.
01-08-1983
Central nervous system toxicity of interferonRohatiner AZ, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA
British Journal of Cancer, Springer Nature vol. 47 (3), 419-422.
01-03-1983
Immune human lymphocytes produce an acid-labile α-interferonBalkwill, Griffin D, Band H, Beverley P
Journal of Experimental Medicine, Rockefeller University Press vol. 157 (3), 1059-1063.
01-03-1983
Interferon in Acute Myelogenous Leukaemia: A Preliminary ReportRohatiner AZS, Balkwill F, Lister TA
, Springer Nature vol. 28, 56-58.
01-01-1983
A Paralytic Disease in Nude Mice Associated with Polyoma Virus InfectionMcCance DJ, Sebesteny A, Griffin BE, Balkwill F, Tilly R, Gregson NA
Journal of General Virology, Microbiology Society vol. 64 (1), 57-67.
01-01-1983
An Animal Model System for Investigating the AntiTumor Effects of Human InterferonBALKWILL FR, MOODIE EM, FREEDMAN V, LANE EB, FANTES KH
Journal of Interferon & Cytokine Research, Mary Ann Liebert vol. 3 (3), 319-326.
01-01-1983
1982
Implications for clinical application of new developments in interferon researchTaylor-Papadimitriou J, Balkwill FR
Biochimica Et Biophysica Acta, Elsevier vol. 695 (1), 49-67.
01-09-1982
Human interferon inhibits the growth of established human breast tumours in the nude mouseBalkwill FR, Moodie EM, Freedman V, Fantes KH
International Journal of Cancer, Wiley vol. 30 (2), 231-235.
15-08-1982
The ppp(A2′p)nA and Protein Kinase Systems in Wild‐Type and Interferon‐Resistant Daudi CellsSILVERMAN RH, WATLING D, BALKWILL FR, TROWSDALE J, KERR IM
The Febs Journal, Wiley vol. 126 (2), 333-341.
01-08-1982
Effects of HuIFN-α2 and HuIFN-α (Namalwa) on Breast Cancer Cells Grown in Culture and as Xenografts in the Nude MouseTAYLOR-PAPADIMITRIOU J, SHEARER M, BALKWILL FR, FANTES KH
Journal of Interferon & Cytokine Research, Mary Ann Liebert vol. 2 (4), 479-491.
01-01-1982
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusionRohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA
Cancer Chemotherapy and Pharmacology, Springer Nature vol. 9 (2), 97-102.
01-01-1982
1981
Extracts from the last century. Mechanical dentistry--on regulation cases by F.H. BalkwillBalkwill FH
British Dental Journal, Springer Nature vol. 151 (1), 19-19.
01-07-1981
Species restriction in cytostatic activity of human and murine monocytes and macrophages.Hogg N, Balkwill FR
Immunology vol. 43 (1), 197-204.
01-05-1981
A Phase I Study of Human Lymphoblastoid Interferon in Patients with Hematological MalignanciesRohatiner A, Balkwill F, Malpas JS, Lister TA
, Springer Nature vol. 26, 63-67.
01-01-1981
A phase I study of intravenous human lymphoblastoid interferon (HLBI)Rohatiner AZS, Balkwill F, Malpas JS, Lister TA
Proceedings of The American Association For Cancer Research vol. Vol. 22
01-01-1981
1980
Demyelination and wasting associated with polyomavirus infection in nude (nu/nu) miceSebesteny A, Tilly R, Balkwill F, Trevan D
Laboratory Animals, Sage Publications vol. 14 (4), 337-345.
01-10-1980
HUMAN LYMPHOBLASTOID INTERFERON CAN INHIBIT THE GROWTH OF HUMAN BREAST CANCER XENOGRAFTS IN ATHYMIC [NUDE] MICEBalkwill F, Taylor‐Papadimitriou J, Fantes KH, Sebesteny A
Annals of The New York Academy of Sciences, Wiley vol. 350 (1), 591-592.
01-10-1980
Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) miceBalkwill F, Taylor-Papadimitriou J, Fantes KH, Sebesteny A
, Elsevier vol. 16 (4), 569-573.
01-04-1980
1979
REMISSION IN ACUTE MYELOBLASTIC LEUKÆMIABalkwill FR, Oliver RTD
The Lancet, Elsevier vol. 314 (8149), 961-962.
01-11-1979
Characterization of human breast milk macrophages cytostatic for human cell lines.Balkwill FR, Hogg N
The Journal of Immunology, Oxford University Press (Oup) vol. 123 (4), 1451-1456.
01-10-1979
Interferons as cell-regulatory moleculesBalkwill FR
Cancer Immunology, Immunotherapy, Springer Nature vol. 7 (1), 7-14.
01-10-1979
1978
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breastBalkwill F, Watling D, Taylor‐Papadimitriou J
International Journal of Cancer, Wiley vol. 22 (3), 258-265.
15-09-1978
Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growthBALKWILL F, TAYLOR-PAPADIMITRIOU J
Nature, Springer Nature vol. 274 (5673), 798-800.
01-08-1978
1977
Growth inhibitory effects of interferon on normal and malignant human haemopoietic cellsBalkwill FR, Oliver RTD
International Journal of Cancer, Wiley vol. 20 (4), 500-505.
15-10-1977
Neoplastic macrophages grown from human leukaemic monocytesBalkwill FR, Franks CR, Oliver RTD, Spector WG
The Journal of Pathology, Wiley vol. 122 (1), 13-26.
01-05-1977
Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived miceFranks CR, Bishop D, Balkwill FR, Oliver RT, Spector WG
British Journal of Cancer, Springer Nature vol. 35 (5), 697-700.
01-05-1977
1976
Diagnostic and prognostic significance of peripheral blood cultural characteristics in adult acute leukaemiaBalkwill FR, Oliver RT
British Journal of Cancer, Springer Nature vol. 33 (4), 400-410.
01-04-1976
Morphological characterisation of adult acute leukaemia in short-term liquid culture.Balkwill FR, Oliver RT
(56), 87-90.
01-01-1976
1974
Factors influencing microculture of leukaemia cellsBALKWILL F, PINDAR A, CROWTHER D
Nature, Springer Nature vol. 251 (5477), 741-742.
01-10-1974
Grants
Grants of specific relevance to Predictive in vitro ModelsREMODEL - ERC AdG 2021 Frances BalkwillFran Balkwill
£2,154,257 EPSRC - EU Scheme
01-10-2022 - 30-09-2027
Evaluation of the cytotoxic function of the AZ CAR-T cell products by employing human in vitro 3 D multicellar models of high grade serous ovarian cancerBeatrice Malacrida and Fran Balkwill
£119,779 AstraZeneca UK Limited
12-09-2024 - 11-09-2025
Studying immune repertoire as an indicator for response to immunotherapy treatment in High-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£24,208 CR-UK Cancer Research UK
15-02-2024 - 14-02-2025
Targeting immune cells to improve response the chemotherapy in high-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£52,374 Barts and the London Charity
01-04-2023 - 31-03-2024
CRUK City of London Centre 2020 Consumables AwardFran Balkwill
£15,000 UCL University College London
03-12-2020 - 31-03-2021
CHILL COGNITION new versionChristopher Griffiths and Fran Balkwill
£302,743 Barts and the London Charity
01-09-2020 - 01-09-2024
Interplay between ovarian cancer stem cells and the tumour microenvironmentFran Balkwill
£230,324 Ovarian Cancer Research Alliance (USA)
01-01-2020 - 31-12-2023
Immunotheraphy and clear cell ovarian cancerFran Balkwill
£290,799 MRC Medical Research Council
01-01-2019 - 30-06-2022
The effect of chemotherapy on Macrophage subpopulations in high-grade ovarian serous carcinomaFran Balkwill
£20,000 Wellbeing of Women
03-12-2018 - 30-11-2020
Targeting the innate immune system in high grade serous ovarian cancerFran Balkwill
£1,924,190 CR-UK Cancer Research UK
01-10-2018 - 31-10-2024
Exploring novel immunotherapy combinations for the treatment of lung cancer- also look at Project 380880Maria Castellano Sanchez and Fran Balkwill
£45,000 ACERTA
26-03-2018 - 15-03-2021
Advanced solid tissue models of T cell migration and activityFran Balkwill
£100,028 BBSRC Biotechnology and Biological Sciences Research Council
02-10-2017 - 25-03-2022
Advanced solid tissue models of T-cell migration and activityFran Balkwill
£32,000 GSK GlaxoSmithKline UK Ltd
01-10-2017 - 25-03-2022
Investigating the tumour extracellular matrix in the inhibition of anti-tumour imunityOliver Pearce and Fran Balkwill
£113,891 UCB Pharma SPRL
01-10-2017 - 28-02-2021
Targeting the peritoneal tumour microenvironment of high grade serous ovarian cancer CIFG1C9RFran Balkwill
£1,652,914 CR-UK Cancer Research UK
01-08-2017 - 31-03-2019
The effects of neo-adjuvant chemotherapy on myleoid cells in high-grade serous ovarian cancer metastases CIFG1E4RFran Balkwill
£313,427 Wellcome Trust
01-05-2016 - 30-04-2019